These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11237260)

  • 1. Inhibition of human topoisomerase II by the antitumor metallocenes.
    Mokdsi G; Harding MM
    J Inorg Biochem; 2001 Jan; 83(2-3):205-9. PubMed ID: 11237260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organometallic anticancer agents: the effect of the central metal and halide ligands on the interaction of metallocene dihalides Cp2MX2 with nucleic acid constituents.
    Murray JH; Harding MM
    J Med Chem; 1994 Jun; 37(13):1936-41. PubMed ID: 8027975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases.
    Yakisich JS; Sidén A; Eneroth P; Cruz M
    Biochem Biophys Res Commun; 2001 Nov; 289(2):586-90. PubMed ID: 11716515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organometallic anticancer agents. 2. Aqueous chemistry and interaction of niobocene dichloride with nucleic acid constituents and amino acids.
    Harding MM; Prodigalidad M; Lynch MJ
    J Med Chem; 1996 Dec; 39(25):5012-6. PubMed ID: 8960562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase II-mediated cleavage of plasmid DNA.
    Burden DA; Froelich-Ammon SJ; Osheroff N
    Methods Mol Biol; 2001; 95():283-9. PubMed ID: 11089240
    [No Abstract]   [Full Text] [Related]  

  • 6. Bimolane: in vitro inhibitor of human topoisomerase II.
    Frantz CE; Smith H; Eades DM; Grosovsky AJ; Eastmond DA
    Cancer Lett; 1997 Dec; 120(2):135-40. PubMed ID: 9461029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucosylated isoflavones as DNA topoisomerase II poisons.
    Martín-Cordero C; López-Lazaro M; Piñero J; Ortiz T; Cortés F; Ayuso MJ
    J Enzyme Inhib; 2000; 15(5):455-60. PubMed ID: 11030085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A (1)H NMR study of the interaction of antitumor metallocenes with glutathione.
    Mokdsi G; Harding MM
    J Inorg Biochem; 2001 Sep; 86(2-3):611-6. PubMed ID: 11566334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour metallocenes: structure-activity studies and interactions with biomolecules.
    Harding MM; Mokdsi G
    Curr Med Chem; 2000 Dec; 7(12):1289-303. PubMed ID: 11032972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy.
    Chourpa I; Morjani H; Riou JF; Manfait M
    FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 31P NMR study of the interaction of the antitumor active metallocene Cp2MoCl2 with calf thymus DNA.
    Harding MM; Harden GJ; Field LD
    FEBS Lett; 1993 May; 322(3):291-4. PubMed ID: 8486161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to topoisomerase II poisons: is the answer in the promoter?
    Kaufmann SH
    Leuk Res; 1997; 21(11-12):1033-6. PubMed ID: 9444936
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
    Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumour activity of cyclopendadienyl-substituted metallocene dihalides in human breast and colon cancer cells.
    Stachtea X; Karamanos N; Klouras N
    Anticancer Res; 2009 Aug; 29(8):3227-31. PubMed ID: 19661339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory properties of antitumor prostaglandins against topoisomerases.
    Suzuki K; Uyeda M
    Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding.
    Sander M; Hsieh T; Udvardy A; Schedl P
    J Mol Biol; 1987 Mar; 194(2):219-29. PubMed ID: 3039151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium.
    Vashisht Gopal YN; Kondapi AK
    J Biosci; 2001 Jun; 26(2):271-6. PubMed ID: 11426063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput-compatible, fluorescence anisotropy-based assay for ATP-dependent supercoiled DNA relaxation by human topoisomerase IIα.
    Shapiro AB
    Biochem Pharmacol; 2013 May; 85(9):1269-77. PubMed ID: 23415903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.
    Drake FH; Hofmann GA; Bartus HF; Mattern MR; Crooke ST; Mirabelli CK
    Biochemistry; 1989 Oct; 28(20):8154-60. PubMed ID: 2557897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.